EDIT Stock - Editas Medicine, Inc.
Unlock GoAI Insights for EDIT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $32.31M | $78.12M | $19.71M | $25.54M | $90.73M |
| Gross Profit | $32.31M | $72.06M | $13.38M | $20.49M | $-67,264,000 |
| Gross Margin | 100.0% | 92.2% | 67.9% | 80.2% | -74.1% |
| Operating Income | $-251,152,000 | $-169,181,000 | $-225,950,000 | $-193,146,000 | $-134,840,000 |
| Net Income | $-237,093,000 | $-153,219,000 | $-220,432,000 | $-192,502,000 | $-115,976,000 |
| Net Margin | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% |
| EPS | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 28th 2025 | H.C. Wainwright | Initiation | Buy | $3 |
| December 16th 2024 | JP Morgan | Downgrade | Underweight | - |
| December 13th 2024 | Chardan Capital Markets | Downgrade | Neutral | - |
| December 13th 2024 | Truist | Downgrade | Hold | - |
| December 13th 2024 | Stifel | Downgrade | Hold | $3← $11 |
| December 11th 2024 | Wells Fargo | Downgrade | Equal Weight | $4← $7 |
| November 25th 2024 | BofA Securities | Downgrade | Underperform | $1← $13 |
| November 6th 2024 | Evercore ISI | Upgrade | Outperform | - |
| November 4th 2024 | Raymond James | Downgrade | Market Perform | - |
| August 8th 2024 | BofA Securities | Upgrade | Buy | $15← $13 |
| May 9th 2024 | Morgan Stanley | Upgrade | Equal Weight | $7 |
| October 24th 2023 | Citigroup | Upgrade | Buy | $11 |
| October 18th 2023 | JP Morgan | Upgrade | Neutral | $8 |
| October 17th 2023 | Cantor Fitzgerald | Downgrade | Neutral | - |
| September 29th 2023 | Stifel | Upgrade | Buy | $17← $9 |
Earnings History & Surprises
EDITEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $-0.27 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.38 | $-0.28 | +26.3% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.41 | $-0.63 | -53.7% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.51 | $-0.43 | +15.7% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $-0.39 | $-0.55 | -41.0% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.76 | $-0.75 | +1.3% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.69 | $-0.82 | -18.8% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.63 | $-0.76 | -20.6% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.52 | $-0.23 | +55.8% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $-0.64 | $-0.55 | +14.1% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.76 | $-0.56 | +26.3% | ✓ BEAT |
Q2 2023 | May 5, 2023 | $-0.79 | $-0.71 | +10.1% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-0.84 | $-0.88 | -4.8% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-0.87 | $-0.81 | +6.9% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.84 | $-0.78 | +7.1% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.81 | $-0.74 | +8.6% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.78 | $-0.61 | +21.8% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.86 | $-0.57 | +33.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.85 | $-0.81 | +4.7% | ✓ BEAT |
Latest News
Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate
📈 PositiveEditas Medicine To Present Data On LDL Cholesterol–Lowering In Vivo Crispr Gene Editing Medicine At American Heart Association Scientific Sessions
📈 PositiveEditas Medicine Reports In Vivo Preclinical Proof-Of-Concept Data For EDIT-401, One-Time Therapy To Significantly Reduce LDL-C, At Annual ESGCT Congress In Seville, Spain
📈 PositiveEditas Medicine To Deliver EDIT-401 Oral Presentation At European Society Of Gene And Cell Therapy Congress, October 7–10, 2025, In Seville, Spain
📈 PositiveHC Wainwright & Co. Reiterates Buy on Editas Medicine, Maintains $5 Price Target
📈 PositiveWells Fargo Maintains Equal-Weight on Editas Medicine, Raises Price Target to $4
➖ NeutralEditas Medicine Announces EDIT-401 As Lead In Vivo Candidate With ~90% LDL-C Reduction And Human Proof-of-Concept By 2026
📈 PositiveFrequently Asked Questions about EDIT
What is EDIT's current stock price?
What is the analyst price target for EDIT?
What sector is Editas Medicine, Inc. in?
What is EDIT's market cap?
Does EDIT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EDIT for comparison